Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.30
−$0.06 · -1.12%
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Previous close
$5.30
−$0.06 · -1.12%
Regular session · ET · Market data may be delayed.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Day range
Current $5.30
52-week range
Current $5.30
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
73
Undervalued
Sentiment
42
Mixed
Risk
69
High Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Day range
Current $5.30
52-week range
Current $5.30
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 35.58M USD | 7.57M USD | 5.12M USD | 9.03M USD | 12M USD |
| Cost of goods sold | 3.44M USD | 2.74M USD | 746K USD | 725K USD | 472K USD |
| Gross profit | 32.14M USD | 4.83M USD | 4.38M USD | 8.31M USD | 11.53M USD |
| Research and development | 8.86M USD | 11.84M USD | 20.3M USD | 12.2M USD | 15.93M USD |
| Selling, general, and administrative | 35.22M USD | 58.82M USD | 47.31M USD | 17.41M USD | 26.98M USD |
| Operating expenses | 44.08M USD | 70.75M USD | 70.14M USD | 29.6M USD | 42.44M USD |
| Interest income | 929K USD | 1.42M USD | 2.74M USD | 476K USD | 123K USD |
| Interest expense | 7.74M USD | 9.41M USD | 3.96M USD | 2.17M USD | 4.3M USD |
| Depreciation and amortization | 781K USD | 1.27M USD | 836K USD | 718K USD | 472K USD |
| Operating income | −11.94M USD | −65.92M USD | −65.76M USD | −21.3M USD | −30.91M USD |
| Net income | −17.89M USD | −76.58M USD | −67M USD | −24.49M USD | −35.08M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.13M0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Extended Market ETFVXF707.13K0.00%93.7B USD0.05%$242.66+0.14%
iShares Micro-Cap ETFIWC188.68K0.01%1.47B USD0.60%$196.25+0.69%
Dimensional - US Small Cap ETFDFAS39.52K0.00%15.54B USD0.26%$82.20+0.18%
U.S. Micro Cap Portfolio ETFDFMC11.19K0.00%7.81B USD0.43%$60.36+0.60%
Dimensional - US Core Equity 1 ETFDCOR8.82K0.00%3.52B USD0.14%$84.83-0.20%
Dimensional - US Core Equity 2 ETFDFAC4.29K0.00%49.14B USD0.17%$45.72-0.09%
Avantis Total Equity Markets ETF 1AVTM2.58K—790.59M USD0.23%$55.77-0.08%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCDimensional - US Core Equity 1 ETFDCORDimensional - US Core Equity 2 ETFDFACAvantis Total Equity Markets ETF 1AVTMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
